In Europe, ADPKD affects about one per 800-1000 people and accounts for 6-10% of end-stage renal disease (ESRD) patients [1-3]. ADPKD is characterized by mutations in polycystic kidney disease 1 (PKD1), polycystic kidney disease 2 (PKD2) and glucosidase II alpha subunit (GANAB) genes that increase the cyclic adenosine monophosphate (cAMP) intracellular levels and upregulate the mammalian target of rapamycin receptor (mTOR). The gene discussed is PKD2; the disease is autosomal dominant polycystic kidney disease.